French pharma company Ipsen (Euronext: IPN) today announced financial results for the first half of 2018, posting group sales of 1.06 billion euros ($1.24 billion), a rise of 21.5%.
Specialty care sales were 920.2 million euros, a rise of 26.7%, while Consumer Healthcare sales were 144.3 million euros, a modest 2.0% rise.
Core operating income came in at 322.5 million euros, a leap of 34.1%, with core earnings per share (EPS) at 2.66 euros, up 40.2%. Core consolidate net profit was 237.1 million euros, an increase of 40.1%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze